Profile

20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended release. Validated as an eye drop, it has a successful lead pre-clinical program in glaucoma for which it is seeking investment. 20/20 OptimEyes is also interested in partners with novel or repurposed APIs targeting mucosal areas for co-development opportunities.

20/20 OptimEyes Technologies Inc. logo

Website

2020optimeyes.ca

Contact


Event details

Date: November 3 - 5, 2025

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

22 in total